bluuebunny/crossref_metadata_2025 huggingface dataset:
Segmented propagation model for the paths and travel times of surface duct leaky signals
Authors: Gong Guangyu , Duan Rui , Yang Kunde
Published: September 2024

In the deep ocean environment with a surface duct, sound propagating within the duct leaks into the geometric shadow zone below it. However, the propagation paths and time of these leaky parts have not been fully characterized. This paper investigates the mechanism of surface duct leaky (SDL) signals based on normal mode theory. It reveals that SDL signals are caused by specific modes with grazing angles close to zero at the bottom of the surface duct. Combining the theory of diffracted sound rays, the study proposes a Segmented Propagation model (SPM) for SDL signals. The propagation paths of SDL signals are divided into three segments: S1, which extends from the source to the surface duct; S2, the segment propagating within the surface duct; and S3, the segment leading from the surface duct to the receiver. The proposed SPM describes the propagation mechanism of SDL signals and allows for precise calculation of their propagation time. Experimental data from the western Pacific are used to verify the SPM.
Motivation Mediating the Relationship Between Needs and Performance in Professional Esports Athletes: A Brief Report
Authors: Obine Emmanuel A.C.
Published: September 2024

Background: Esports is a growing industry, and understanding the underlying professional esports athletes’ experiences can have an impact on their performance and coaching approaches. The present study investigated the mediating role of types of motivations in the relationship between psychological needs (autonomy, competence, and relatedness) and performance (shooting accuracy and time trial). Method: A total of 113 esports athletes (13 females and 100 males) with an average age of 21.42 (SD = 2.893) participated in the study. The participants first answered a questionnaire to measure their needs and motivations and then completed an esports task in Counter-Strike. The collected data were analyzed using a causal-step method for mediation analysis. Results: The study found that competence needs significantly correlated with performance measures. Intrinsic and introjected motivations significantly mediated the relationship between competence and performance outcomes. Conclusion: The present study suggests that satisfying the need for mastery has a direct impact on esports athletes’ motivation, which in turn affects their performance positively due to their passion and perceived self-esteem. When interpreting the results, it is important to consider the study’s limitations, which are further discussed in the discussion section.
A Walkthrough of ActiGraph Counts
Authors: Neishabouri Ali , Nguyen Joe , Patterson Matthew R. , Pilkar Rakesh , Guo Christine C.
Published: September 2024

Activity counts have been used for over two decades with over 22,000 published scientific papers in public health and clinical research. ActiGraph recently released the algorithm for computing counts from raw accelerometer data as an open-source Python library, which is now ported by researchers to other languages, notably R. The current commentary presents historical overview of ActiGraph counts, and its development and evolution as a measure of physical activity. Further, we provide general recommendations on extracting counts from raw accelerometer data and discuss specific considerations with respect to device types, resampling, nonwear, axes orientations, and epoch length that may influence counts. Last, we provide a tutorial on how to use ActiGraph’s open-source Python library, agcounts, for consistent, accurate, and reproducible count. We expect this commentary will provide familiarity and transparency needed to adopt and produce activity counts in a consistent manner, allowing researchers to conduct statistical comparisons across multiple data sets and studies.
Optogenetic control of
Drosophila
neurons: a laboratory practical for undergraduates and outreach
Authors: Renault Andrew D.
Published: September 2024

Teaching aspects of neuroscience to large undergraduate classes can be difficult in terms of the cost of equipment involved such as microscopes and electrophysiology equipment, the time taken to master techniques such as dissection or intracellular recording, and ethical concerns when using vertebrates. Here, I describe a practical that uses behavioral readouts and optogenetics on
Drosophila
that can be implemented with minimal cost as well as reduced ethical concerns and uses mostly observational techniques. The practical can be used to teach aspects of genetics and the tools for manipulating neuronal activity for ascribing neuronal function. The practical can be customized to fit different undergraduate levels and learning objectives.
Supplemental Material: The composite metamorphic sequence in the Jiajika gneiss dome, Songpan-Ganze orogenic belt, eastern Tibet: P-T-D-t evolution and implications for lithium mineralization
Authors: Zhu Junyue , Zhu Wenbin , al. et
Published: September 2024

The analytical methods, the calculation of the effective bulk composition, the electron probe microanalysis data, the whole-rock major element data, the geochronology and trace element data of monazite and titanite, and Supplemental Figures S1 and S2.
Short-term choroidal changes as early indicators for future myopic shift in primary school children: results of a 2-year cohort study
Authors: Wu Hao , Liu Mengqi , Wang Yuanyuan , Li Xiang , Zhou Weihe , Li Haoer , Xie Zhu , Wang Pengqi , Zhang Tingting , Qu Wei , Huang Jing , Zhao Yunpeng , Wang Jiefang , Zhang Sen , Qu Jia , Ye Cong , Zhou Xiangtian
Published: September 2024

Background

To assess predictive value of short-term choroidal changes for future myopic shift in children.

Methods

577 eyes of 289 primary school children were prospectively followed for 2 years. Cycloplegic refractions at baseline, 1 year and 2 years, and choroidal measurements by optical coherence tomography at baseline and 3 months, were used for analyses. Myopic shift was defined as refraction change of at least −0.50 dioptre/year, at 2 years compared with baseline.

Results

228 participants (455 eyes) completed 2-year follow-up. Approximately 37.6% of 311 initially non-myopic eyes and 73.6% of 144 initially myopic eyes developed a myopic shift. Notably, at 3 months greater reductions were found in initially myopic eyes with myopic shift, than in those without myopic shift—in choroidal thickness (ChT), luminal area (LA), stromal area (SA) and total choroidal area (TCA), but no significant differences in any choroidal parameters were observed between non-myopic eyes, with and without myopic shift. Multivariable analyses showed that in myopic eyes, each percentage increase in ChT, LA, SA and TCA was associated with reduced odds of myopic shift (all p<0.001). Similar associations were observed in non-myopic eyes, with smaller effects than in myopic eyes. Adding a 3-month percentage change of each choroidal parameter to a basic model including age, gender, parental myopia and baseline refraction significantly improved the predictive performance in myopic eyes (area under the receiver operating characteristic curves increasing from 0.650 to approximately 0.800, all p<0.05), but not in non-myopic eyes.

Conclusion

Short-term choroidal changes could act as early indicators for future myopic shift in children.
Developing an exercise intervention to minimise hip bone mineral density loss following traumatic lower limb amputation: a Delphi study
Authors: Behan Fearghal P , Bull Anthony M J , Beck Belinda R , Brooke-Wavell Katherine , Müller Ralph , Vico Laurence , Isaksson Hanna , Harvey Nicholas C , Buis Arjan , Sherman Kate , Jefferson Gemma , Cleather Daniel J , McGregor Alison , Bennett Alexander N
Published: September 2024

Objective

To elicit expert opinion and gain consensus on specific exercise intervention parameters to minimise hip bone mineral density (BMD) loss following traumatic lower limb amputation.

Methods

In three Delphi rounds, statements were presented to a panel of 13 experts from six countries. Experts were identified through publications or clinical expertise. Round 1 involved participants rating their agreement with 22 exercise prescription statements regarding BMD loss post amputation using a 5-point Likert scale. Agreement was deemed as 3–4 on the scale (agree/strongly agree). Statements of <50% agreement were excluded. Round 2 repeated remaining statements alongside round 1 feedback. Round 3 allowed reflection on round 2 responses considering group findings and the chance to change or maintain the resp onse. Round 3 statements reaching ≥70% agreement were defined as consensus.

Results

All 13 experts completed rounds 1, 2 and 3 (100% completion). Round 1 excluded 12 statements and added 1 statement (11 statements for rounds 2–3). Round 3 reached consensus on nine statements to guide future exercise interventions. Experts agreed that exercise interventions should be performed at least 2 days per week for a minimum of 6 months, including at least three different resistance exercises at an intensity of 8–12 repetitions. Interventions should include weight-bearing and multiplanar exercises, involve high-impact activities and be supervised initially.

Conclusion

This expert Delphi process achieved consensus on nine items related to exercise prescription to minimise hip BMD loss following traumatic lower limb amputation. These recommendations should be tested in future interventional trials.
Is it possible to identify populations experiencing material disadvantage in primary care? A feasibility study using the Clinical Practice Research Database
Authors: Davies Laurie E , Sinclair David R , Kingston Andrew , Spiers Gemma Frances , Hanratty Barbara
Published: September 2024

Background

Material disadvantage is associated with poor health, but commonly available area-based metrics provide a poor proxy for it. We investigate if a measure of material disadvantage could be constructed from UK primary care electronic health records.

Methods

Using data from Clinical Practice Research Datalink Aurum (May 2022) linked to the 2019 English Index of Multiple Deprivation (IMD), we sought to (1) identify codes that signified material disadvantage, (2) aggregate these codes into a binary measure of material disadvantage and (3) compare the proportion of people with this binary measure against IMD quintiles for validation purposes.

Results

We identified 491 codes related to benefits, employment, housing, income, environment, neglect, support services and transport. Participants with one or more of these codes were defined as being materially disadvantaged. Among 30,897,729 research-acceptable patients aged ≥18 with complete data, only 6.1% (n=1,894,225) were classified as disadvantaged using our binary measure, whereas 42.2% (n=13,038,085) belonged to the two most deprived IMD quintiles.

Conclusion

Data in a major primary care research database do not currently contain a useful measure of individual-level material disadvantage. This represents an omission of one of the most important health determinants. Consideration should be given to creating codes for use by primary care practitioners.
The relationship between nutritional status and thyroid function among adults in the USA: NHANES 2007–2012
Authors: Liu Junru , Lu Xiaofeng , Wang Xiaohui , Song Jialu , Zhu Xiaotao , Tong Huijing , Xu Chaoyang , Qian Jinfang , Zheng Xiaogang , Wang Mingzheng
Published: September 2024

Controlled Nutritional Status (CONUT) scores have been developed as quantitative tools that can be employed to gauge the nutritional status of individual patients. However, there has been very little research investigating the association between these CONUT scores and the function of the thyroid. As such, the present study was designed to address this research gap through the evaluation of a representative cohort of American adults. National Health and Nutrition Examination Survey (NHANES) data were herein used to separate subjects into those with normal nutritional status (CONUT score: 0–1) from those who were malnourished (CONUT scores > 1). Associations between these CONUT scores and the function of the thyroid were investigated through linear regression modeling, employing weighted analytical strategies and subgroup analyses. Overall, 8082 individuals from the NHANES 2007–2012 cohort were enrolled in this analysis. The weighted mean CONUT score for these individuals was 0.72 (0.02), with 6661 participants (weighted proportion: 83.12%) falling within the normal nutritional status group and 1421 participants (weighted proportion: 16.88%) within the malnourished group. In adjusted analyses, subjects who were malnourished were found to present with an increase in FT4 levels ( β = 0.033; p < 0.001 together with reduced TT3 levels ( β = −3.526; p = 0.01). The present data offer evidence in support of higher CONUT scores, which correspond to malnutrition, being related to increases in FT4 levels together with reductions in TT3 levels. More studies will be crucial to further probe the mechanistic drivers of these results.
Supplementary Figure S9 from Long-Term Risks of Cardiovascular Death among Older Patients with Major Hematological Malignancies: A Population-Based Cohort Study from SEER Database
Authors: Zhang Hanqing , He Minghao , Zhang Peng , Gao Yang , Ouyang Ling , He Xianjun , Han Na , Zhang Jinfeng , Guan Mengshan , Feng Yueqi , Li Yonghua
Published: September 2024

Supplementary Figure S9. The cumulative mortality in older patients with hematological malignancies based on clinical features. For each panel, we show the cumulative mortality curve for older patients among different types of hematological malignancy base on different clinical features: age at diagnosis, sex, race, Ann Arbor stage and radiation information. Abbreviations: CVD, Cardiovascular Disease
Supplementary Figure S11 from Long-Term Risks of Cardiovascular Death among Older Patients with Major Hematological Malignancies: A Population-Based Cohort Study from SEER Database
Authors: Zhang Hanqing , He Minghao , Zhang Peng , Gao Yang , Ouyang Ling , He Xianjun , Han Na , Zhang Jinfeng , Guan Mengshan , Feng Yueqi , Li Yonghua
Published: September 2024

Supplementary Figure S11. The cumulative mortality among older patients with hematological malignancies based on different types of hematological malignancy (age at diagnosis: 75-84). For each panel, we show the cumulative mortality curve for older patients among all 7 types of hematological malignancies: acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma. Abbreviations: CVD, Cardiovascular Disease
Supplementary Table S2 from Exercise and QUality Diet after Leukemia: A Randomized Weight Loss Trial among Adult Survivors of Childhood Leukemia in the Childhood Cancer Survivor Study
Authors: Friedman Danielle N. , Chou Joanne F. , Clark Jeanne M. , Moskowitz Chaya S. , Ford Jennifer S. , Armstrong Gregory T. , Mubdi Nidha Z. , McDonald Aaron , Nathan Paul C. , Sklar Charles A. , Ramanathan Lakshmi V. , Robison Leslie L. , Oeffinger Kevin C. , Tonorezos Emily S.
Published: September 2024

Supplementary Table S2. Secondary weight loss measures among participants in the EQUAL Study.
Supplementary Table S3 from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
Authors: van Berge Henegouwen Jade M. , Zeverijn Laurien J. , Geurts Birgit S. , Hoes Louisa R. , van der Wijngaart Hanneke , van der Noort Vincent , Huitema Alwin D.R. , de Vos Filip Y.F. , Grünberg Katrien , Bloemendal Haiko J. , Verheul Henk M.W. , Voest Emile E. , Gelderblom Hans
Published: September 2024

Clinical outcome for all included DRUP patients for whom outcome data were available (n = 1006),
stratified according to waiver receival, for the different treatment categories
Supplementary Table 1 from A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Authors: Choudhury Noura J. , Lai W. Victoria , Makhnin Alex , Heller Glenn , Eng Juliana , Li Bob , Preeshagul Isabel , Santini Fernando C. , Offin Michael , Ng Kenneth , Paik Paul , Larsen Christina , Ginsberg Michelle S. , Lau Yvonne , Zhang Xinyuan , Baine Marina K. , Rekhtman Natasha , Rudin Charles M.
Published: September 2024

Dose reductions
Supplementary Figure S3 from Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Authors: Lee Horace H.Y. , Chow Kin Long , Wong Ho Shing , Chong Tsz Yan , Wong Alice S.T. , Cheng Grace H.W. , Ko Jasmine M.K. , Siu Hoi Cheong , Yeung Maximus C.F. , Huen Michael S.Y. , Tse Ka Yu , Bray Mark R. , Mak Tak Wah , Leung Suet Yi , Ip Philip P.C.
Published: September 2024

Supplementary Figure S3. Autopsy findings on a representative mouse treated with 7.5 mg/kg CFI-400945 (hematoxylin and eosin staining).
Table S1 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Authors: Geurts Birgit S. , Zeverijn Laurien J. , Leek Lindsay V.M. , van Berge Henegouwen Jade M. , Hoes Louisa R. , van der Wijngaart Hanneke , van der Noort Vincent , van de Haar Joris , van Ommen-Nijhof Annemiek , Kok Marleen , Roepman Paul , Jansen Anne M.L. , de Leng Wendy W.J. , de Jonge Maja J.A. , Hoeben Ann , van Herpen Carla M.L. , Westgeest Hans M. , Wessels Lodewyk F.A. , Verheul Henk M.W. , Gelderblom Hans , Voest Emile E.
Published: September 2024

Table S1. Overview per patient.
Supplementary Table S2 from Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple Myeloma
Authors: Lozano Ester , Mena Mari-Pau , Garrabou Glòria , Cardús Oriol , Díaz Tania , Moreno David F. , Mañé-Pujol Joan , Oliver-Caldés Aina , Battram Anthony , Tovar Natalia , Cibeira María-Teresa , Rodríguez-Lobato Luis-Gerardo , Bladé Joan , Fernández de Larrea Carlos , Rosiñol Laura
Published: September 2024

Gene expression analysis of CD8 T cells in the presence of PVR or Nectin-2
Supplementary Figure S2 from Increased PVR Expression on Bone Marrow Macrophages May Promote Resistance to TIGIT Blockade in Multiple Myeloma
Authors: Lozano Ester , Mena Mari-Pau , Garrabou Glòria , Cardús Oriol , Díaz Tania , Moreno David F. , Mañé-Pujol Joan , Oliver-Caldés Aina , Battram Anthony , Tovar Natalia , Cibeira María-Teresa , Rodríguez-Lobato Luis-Gerardo , Bladé Joan , Fernández de Larrea Carlos , Rosiñol Laura
Published: September 2024

Supplementary Figure S2: Expression of TIGIT axis on CD14+ and PCs
Supplementary Figure S7 from Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
Authors: French Jena D. , Haugen Bryan R. , Worden Francis P. , Bowles Daniel W. , Gianoukakis Andrew G. , Konda Bhavana , Dadu Ramona , Sherman Eric J. , McCue Shaylene , Foster Nathan R. , Nikiforov Yuri E. , Farias Ticiana D.J. , Norman Paul J. , Wirth Lori J.
Published: September 2024

NLR and MLR before and on treatment
Supplemental Figure 1 from Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Authors: Lenis Andrew T. , Ravichandran Vignesh , Brown Samantha , Alam Syed M. , Katims Andrew , Truong Hong , Reisz Peter A. , Vasselman Samantha , Nweji Barbara , Autio Karen A. , Morris Michael J. , Slovin Susan F. , Rathkopf Dana , Danila Daniel , Woo Sungmin , Vargas Hebert A. , Laudone Vincent P. , Ehdaie Behfar , Reuter Victor , Arcila Maria , Berger Michael F. , Viale Agnes , Scher Howard I. , Schultz Nikolaus , Gopalan Anuradha , Donoghue Mark T.A. , Ostrovnaya Irina , Stopsack Konrad H. , Solit David B. , Abida Wassim
Published: September 2024

Supplemental Figure 1
Supplementary Figure S4 from Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Authors: El Zarif Talal , Meador Catherine B. , Qiu Xintao , Seo Ji-Heui , Davidsohn Matthew P. , Savignano Hunter , Lakshminarayanan Gitanjali , McClure Heather M. , Canniff John , Fortunato Brad , Li Rong , Banwait Mandeep K. , Semaan Karl , Eid Marc , Long Henry , Hung Yin P. , Mahadevan Navin R. , Barbie David A. , Oser Matthew G. , Piotrowska Zofia , Choueiri Toni K. , Baca Sylvan C. , Hata Aaron N. , Freedman Matthew L. , Berchuck Jacob E.
Published: September 2024

Venn diagram showing overlap of LUAD, transformed SCLC, and de novo SCLC PDXs H3K27ac ChIP-seq, H3K4me3 ChIP-seq, ATAC-seq, and MeDIP-seq peaks.
Supplementary Figure S3 from Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Authors: El Zarif Talal , Meador Catherine B. , Qiu Xintao , Seo Ji-Heui , Davidsohn Matthew P. , Savignano Hunter , Lakshminarayanan Gitanjali , McClure Heather M. , Canniff John , Fortunato Brad , Li Rong , Banwait Mandeep K. , Semaan Karl , Eid Marc , Long Henry , Hung Yin P. , Mahadevan Navin R. , Barbie David A. , Oser Matthew G. , Piotrowska Zofia , Choueiri Toni K. , Baca Sylvan C. , Hata Aaron N. , Freedman Matthew L. , Berchuck Jacob E.
Published: September 2024

Unsupervised hierarchical clustering of LUAD, transformed SCLC, and de novo SCLC PDXs for ATAC-seq, H3K27ac ChIP-seq, H3K4me3 ChIP-seq, H3K27me3 ChIP-seq, and MeDIP-seq data.
Supplementary Figure S1 from Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Authors: El Zarif Talal , Meador Catherine B. , Qiu Xintao , Seo Ji-Heui , Davidsohn Matthew P. , Savignano Hunter , Lakshminarayanan Gitanjali , McClure Heather M. , Canniff John , Fortunato Brad , Li Rong , Banwait Mandeep K. , Semaan Karl , Eid Marc , Long Henry , Hung Yin P. , Mahadevan Navin R. , Barbie David A. , Oser Matthew G. , Piotrowska Zofia , Choueiri Toni K. , Baca Sylvan C. , Hata Aaron N. , Freedman Matthew L. , Berchuck Jacob E.
Published: September 2024

Gene expression for ASCL1, NEUROD1, POU2F3, and YAP1 in the SCLC PDXs.
Supplementary Figures 1 from Computational Model Predicts Patient Outcomes in Luminal B Breast Cancer Treated with Endocrine Therapy and CDK4/6 Inhibition
Authors: Schmiester Leonard , Brasó-Maristany Fara , González-Farré Blanca , Pascual Tomás , Gavilá Joaquín , Tekpli Xavier , Geisler Jürgen , Kristensen Vessela N. , Frigessi Arnoldo , Prat Aleix , Köhn-Luque Alvaro
Published: September 2024

Supplementary figures S1-S11
Supplemental Figure 4 from Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Authors: Chen Monica F. , Yang Soo-Ryum , Tao Jessica J. , Desilets Antoine , Diamond Eli L. , Wilhelm Clare , Rosen Ezra , Gong Yixiao , Mullaney Kerry , Torrisi Jean , Young Robert J. , Somwar Romel , Yu Helena A. , Kris Mark G. , Riely Gregory J. , Arcila Maria E. , Ladanyi Marc , Donoghue Mark T.A. , Rosen Neal , Yaeger Rona , Drilon Alexander , Murciano-Goroff Yonina R. , Offin Michael
Published: September 2024

Supplemental Figure 4. Oncoprint for de novo BRAF fusions.
Supplementary Figure S2 from Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Authors: Pourmaleki Maryam , Jones Caitlin J. , Mellinghoff Sabrina D. , Greenstein Brian D. , Kumar Priyadarshini , Foronda Miguel , Navarrete Daniel A. , Campos Carl , Roshal Mikhail , Schultz Nikolaus , Shah Sohrab P. , Schietinger Andrea , Socci Nicholas D. , Hollmann Travis J. , Dogan Ahmet , Mellinghoff Ingo K.
Published: September 2024

Supplementary Figure S2. Tracking of cell loss across staining cycles.
Supplementary Table S1 from Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Authors: Choi Yoonha , Dharia Neekesh V. , Jun Tomi , Chang Julie , Royer-Joo Stephanie , Yau Kenneth K. , Assaf Zoe J. , Aimi Junko , Sivakumar Smruthy , Montesion Meagan , Sacher Adrian , LoRusso Patricia , Desai Jayesh , Schutzman Jennifer L. , Shi Zhen
Published: September 2024

Representativeness of Study Participants
Supplementary Table S4 from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Authors: Jank Paul , Karn Thomas , van Mackelenbergh Marion , Lindner Judith , Treue Denise , Huober Jens , Engels Knut , Solbach Christine , Diebold Kurt , Marmé Frederik , Müller Volkmar , Schneeweiss Andreas , Sinn Hans-Peter , Fehm Tanja , Schem Christian , Stickeler Elmar , Fasching Peter , Budczies Jan , Felder Bärbel , Nekljudova Valentina , Holtschmidt Johannes , Untch Michael , Denkert Carsten , Loibl Sibylle
Published: September 2024

Logistic regression model using PIK3CA mutation level status predicting pCR as binary endpoint in molecular subtypes and in HER2pos cohort stratified by HR status.
Supplementary Data1 from Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma
Authors: Forster Martin , Brana Irene , Pousa Antonio L. , Doger Bernard , Roxburgh Patricia , Bajaj Pawan , Peguero Julio , Krebs Matthew , Carcereny Enric , Patel Grisma , Mueller Christian , Brignone Chrystelle , Triebel Frederic
Published: September 2024

Table S1 Table S2 added (Representativeness of Study Participants), Figures S1 to S3 Figure S4 added to replace data not shown in the main text
Supplementary Table S3 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Authors: Suvilesh Kanve N. , Manjunath Yariswamy , Nussbaum Yulia I. , Gadelkarim Mohamed , Raju Murugesan , Srivastava Akhil , Li Guangfu , Warren Wesley C. , Shyu Chi-Ren , Gao Feng , Ciorba Matthew A. , Mitchem Jonathan B. , Rachagani Satyanarayana , Kaifi Jussuf T.
Published: September 2024

Supplementary Table S3. Clinicopathological information of the surgical NSCLC patients (n = 14) used to validate the PDTO findings.
Data from Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Authors: El Zarif Talal , Meador Catherine B. , Qiu Xintao , Seo Ji-Heui , Davidsohn Matthew P. , Savignano Hunter , Lakshminarayanan Gitanjali , McClure Heather M. , Canniff John , Fortunato Brad , Li Rong , Banwait Mandeep K. , Semaan Karl , Eid Marc , Long Henry , Hung Yin P. , Mahadevan Navin R. , Barbie David A. , Oser Matthew G. , Piotrowska Zofia , Choueiri Toni K. , Baca Sylvan C. , Hata Aaron N. , Freedman Matthew L. , Berchuck Jacob E.
Published: September 2024

AbstractPurpose:
Histologic transformation to small cell lung cancer (SCLC) is a mechanism of treatment resistance in patients with advanced oncogene-driven lung adenocarcinoma (LUAD) that currently requires histologic review for diagnosis. Herein, we sought to develop an epigenomic cell-free DNA (cfDNA)-based approach to noninvasively detect small cell transformation in patients with EGFR mutant (EGFRm) LUAD.
Experimental Design:
To characterize the epigenomic landscape of transformed (t)SCLC relative to LUAD and de novo SCLC, we performed chromatin immunoprecipitation sequencing (ChIP-seq) to profile the histone modifications H3K27ac, H3K4me3, and H3K27me3; methylated DNA immunoprecipitation sequencing (MeDIP-seq); assay for transposase-accessible chromatin sequencing; and RNA sequencing on 26 lung cancer patient-derived xenograft (PDX) tumors. We then generated and analyzed H3K27ac ChIP-seq, MeDIP-seq, and whole genome sequencing cfDNA data from 1 mL aliquots of plasma from patients with EGFRm LUAD with or without tSCLC.
Results:
Analysis of 126 epigenomic libraries from the lung cancer PDXs revealed widespread epigenomic reprogramming between LUAD and tSCLC, with a large number of differential H3K27ac (n = 24,424), DNA methylation (n = 3,298), and chromatin accessibility (n = 16,352) sites between the two histologies. Tumor-informed analysis of each of these three epigenomic features in cfDNA resulted in accurate noninvasive discrimination between patients with EGFRm LUAD versus tSCLC [area under the receiver operating characteristic curve (AUROC) = 0.82–0.87]. A multianalyte cfDNA-based classifier integrating these three epigenomic features discriminated between EGFRm LUAD versus tSCLC with an AUROC of 0.94.
Conclusions:
These data demonstrate the feasibility of detecting small cell transformation in patients with EGFRm LUAD through epigenomic cfDNA profiling of 1 mL of patient plasma.
Data from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
Authors: Pakola Santeri A. , Peltola Katriina J. , Clubb James H.A. , Jirovec Elise , Haybout Lyna , Kudling Tatiana V. , Alanko Tuomo , Korpisaari Riitta , Juteau Susanna , Jaakkola Marjut , Sormunen Jorma , Kemppainen Jukka , Hemmes Annabrita , Pellinen Teijo , van der Heijden Mirte , Quixabeira Dafne C.A. , Kistler Claudia , Sorsa Suvi , Havunen Riikka , Santos Joao M. , Cervera-Carrascon Victor , Hemminki Akseli
Published: September 2024

AbstractPurpose:
TILT-123 (igrelimogene litadenorepvec) is an oncolytic adenovirus armed with TNFa and IL2, designed to induce T-cell infiltration and cytotoxicity in solid tumors.
Patients and Methods:
TUNIMO (NCT04695327) was a single-arm, multicenter phase I dose-escalation trial designed to assess the safety of TILT-123 in advanced solid cancers refractory to standard therapy. Patients received intravenous and intratumoral TILT-123. The primary endpoint was safety by adverse events (AE), laboratory values, vital signs, and electrocardiograms. Secondary endpoints included tumor response, pharmacokinetics, and predictive biomarkers.
Results:
Twenty patients were enrolled, with a median age of 58 years. Most prevalent cancer types included sarcomas (35%), melanomas (15%) and ovarian cancers (15%). No dose-limiting toxicities were observed. The most frequent treatment-related AEs included fever (16.7%), chills (13.0%), and fatigue (9.3%). Ten patients were evaluable for response on day 78 with RECIST 1.1, iRECIST or PET-based evaluation. The disease control rate by PET was 6/10 (60% of evaluable patients) and 2/10 by RECIST 1.1 and iRECIST(20%of evaluable patients). Tumor size reductions occurred in both injected and non-injected lesions. TILT-123 was detected in injected and non-injected tumors, and virus was observed in blood after intravenous and intratumoral injections. Treatment resulted in reduction of lymphocytes in blood, with concurrent lymphocyte increases in tumors, findings compatible with trafficking.
Conclusions:
TILT-123 was safe and able to produce antitumor effects in local and distant lesions in heavily pre-treated patients. Good tolerability of TILT-123 facilitates combination studies, several of which are ongoing (NCT04217473, NCT05271318, NCT05222932, and NCT06125197).

See related commentary by Silva-Pilipich and Smerdou, p. 3649
Data from An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Authors: Jank Paul , Karn Thomas , van Mackelenbergh Marion , Lindner Judith , Treue Denise , Huober Jens , Engels Knut , Solbach Christine , Diebold Kurt , Marmé Frederik , Müller Volkmar , Schneeweiss Andreas , Sinn Hans-Peter , Fehm Tanja , Schem Christian , Stickeler Elmar , Fasching Peter , Budczies Jan , Felder Bärbel , Nekljudova Valentina , Holtschmidt Johannes , Untch Michael , Denkert Carsten , Loibl Sibylle
Published: September 2024

AbstractPurpose:
The PI3K signaling pathway is frequently dysregulated in breast cancer, and mutations in PIK3CA are relevant for therapy resistance in HER2-positive (HER2pos) breast cancer. Mutations in exons 9 or 20 may have different impacts on response to neoadjuvant chemotherapy-based treatment regimens.
Experimental Design:
We investigated PIK3CA mutations in 1,691 patients with early breast cancer who were randomized into four neoadjuvant multicenter trials: GeparQuattro (NCT00288002), GeparQuinto (NCT00567554), GeparSixto (NCT01426880), and GeparSepto (NCT01583426). The role of different PIK3CA exons and hotspots for pathologic complete response (pCR) following neoadjuvant chemotherapy (NACT) and patient survival were evaluated for distinct molecular subgroups and anti-HER2 treatment procedures.
Results:
A total of 302 patients (17.9%) of the full cohort of 1,691 patients had a tumor with a PIK3CA mutation, with a different prevalence in molecular subgroups: luminal/HER2-negative (HER2neg) 95 of 404 (23.5%), HER2pos 170 of 819 (20.8%), and triple-negative breast cancer 37 of 468 patients (7.9%). We identified the mutations in PIK3CA exon 20 to be linked with worse response to anti-HER2 treatment (OR = 0.507; 95% confidence interval, 0.320–0.802; P = 0.004), especially in hormone receptor–positive HER2-positive breast cancer (OR = 0.445; 95% confidence interval, 0.237–0.837; P = 0.012). In contrast, exon 9 hotspot mutations p.E452K and p.E545K revealed no noteworthy differences in response therapy. Luminal/HER2neg patients show a trend to have worse treatment response when PIK3CA was mutated. Interestingly, patients with residual disease following neoadjuvant treatment had better survival rates when PIK3CA was mutated.
Conclusions:
The PIK3CA hotspot mutation p.H1047R is associated with worse pCR rates following NACT in HER2pos breast cancer, whereas hotspot mutations in exon 9 seem to have less impact.
Figure S17 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Authors: Skadborg Signe K. , Maarup Simone , Draghi Arianna , Borch Annie , Hendriksen Sille , Mundt Filip , Pedersen Vilde , Mann Matthias , Christensen Ib J. , Skjøth-Ramussen Jane , Yde Christina W. , Kristensen Bjarne W. , Poulsen Hans S. , Hasselbalch Benedikte , Svane Inge M. , Lassen Ulrik , Hadrup Sine R.
Published: September 2024

Verification of detected NARTs.
Figure S12 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
Authors: Skadborg Signe K. , Maarup Simone , Draghi Arianna , Borch Annie , Hendriksen Sille , Mundt Filip , Pedersen Vilde , Mann Matthias , Christensen Ib J. , Skjøth-Ramussen Jane , Yde Christina W. , Kristensen Bjarne W. , Poulsen Hans S. , Hasselbalch Benedikte , Svane Inge M. , Lassen Ulrik , Hadrup Sine R.
Published: September 2024

Gating strategy for T-cell reactivity assay.
Supplementary Figure S6 from PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination
Authors: Franzolin Giulia , Brundu Serena , Cojocaru Carina F. , Curatolo Aurora , Ponzo Matteo , Mastrantonio Roberta , Mihara Emiko , Kumanogoh Atsushi , Suga Hiroaki , Takagi Junichi , Tamagnone Luca , Giraudo Enrico
Published: September 2024

The treatment with Fc(m6A9)B3 PLXNB1 inhibitor decreases M2-like macrophages and enhances the number of CD8+ GrzB+ T-cells in Py230 model
Supplementary Figure S2 from PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination
Authors: Franzolin Giulia , Brundu Serena , Cojocaru Carina F. , Curatolo Aurora , Ponzo Matteo , Mastrantonio Roberta , Mihara Emiko , Kumanogoh Atsushi , Suga Hiroaki , Takagi Junichi , Tamagnone Luca , Giraudo Enrico
Published: September 2024

PLXNB1 depletion induces tumor vessel normalization and reduces tumor hypoxia
Supplementary Figure S5 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Authors: Sulsenti Roberta , Scialpi Giuseppina B. , Frossi Barbara , Botti Laura , Ferri Renata , Tripodi Irene , Piva Annamaria , Sangaletti Sabina , Pernici Davide , Cancila Valeria , Romeo Francesco , Chiodoni Claudia , Lecis Daniele , Bianchi Francesca , Fischetti Irene , Enriquez Claudia , Crivelli Filippo , Bregni Marco , Renne Giuseppe , Pece Salvatore , Tripodo Claudio , Pucillo Carlo E. , Colombo Mario P. , Jachetti Elena
Published: September 2024

Supplementary Figure S5. Expression of OPN in MC/9 cells and effect on T23 cell proliferation. A. Separate channels of immunofluorescence for DAPI (cyan), OPN (red) and WGA (blue) of MC/9, MC/9-CTR, MC/9-OPNf, and MC/9-iOPN cells showed in Fig. 2E. B. Quantification of A as percentage of OPN positive cells. C. Murine adenocarcinoma (T23) cells (50.000/well) were cultured either alone or with MC/9, MC/9-CTR, MC/9-OPNf or MC/9-iOPN cells (tumor cell:MC ratio 1:1). After 4 days the growth rate of cancer cells was evaluated through trypan blue count. Cancer cells and MC/9 could be distinguished thanks to their grown in adhesion or suspension, respectively. All histograms depict mean ± SD of biological replicates (represented by dots). One-way ANOVA followed by Tukey’s multiple comparison test was used: *, P < 0.05; **, P <0.01. Where P-value is not indicated, the comparison between groups is not statistically significant.
Figure S2 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Authors: Oberstein Paul E. , Dias Costa Andressa , Kawaler Emily A. , Cardot-Ruffino Victoire , Rahma Osama E. , Beri Nina , Singh Harshabad , Abrams Thomas A. , Biller Leah H. , Cleary James M. , Enzinger Peter , Huffman Brandon M. , McCleary Nadine J. , Perez Kimberly J. , Rubinson Douglas A. , Schlechter Benjamin L. , Surana Rishi , Yurgelun Matthew B. , Wang S. Jennifer , Remland Joshua , Brais Lauren K. , Bollenrucher Naima , Chang Eugena , Ali Lestat R. , Lenehan Patrick J. , Dolgalev Igor , Werba Gregor , Lima Cibelle , Keheler C. Elizabeth , Sullivan Keri M. , Dougan Michael , Hajdu Cristina , Dajee Maya , Pelletier Marc R. , Nazeer Saloney , Squires Matthew , Bar-Sagi Dafna , Wolpin Brian M. , Nowak Jonathan A. , Simeone Diane M. , Dougan Stephanie K.
Published: September 2024

Supplemental Figure 2: Pharmacokinetics of canakinumab. Serum levels of canakinumab were measured in patients on SR-1 at the indicated time points.
Table S2 from Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion
Authors: De Munter Stijn , Buhl Juliane L. , De Cock Laurenz , Van Parys Alexander , Daneels Willem , Pascal Eva , Deseins Lucas , Ingels Joline , Goetgeluk Glenn , Jansen Hanne , Billiet Lore , Pille Melissa , Van Duyse Julie , Bonte Sarah , Vandamme Niels , Van Dorpe Jo , Offner Fritz , Leclercq Georges , Taghon Tom , Depla Erik , Tavernier Jan , Kerre Tessa , Drost Jarno , Vandekerckhove Bart
Published: September 2024

Differentially expressed genes in nanoCAR T-cells from cluster CD8KO vs CD8WT
Supplementary Figure 2 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy
Authors: Porte Sarah , Audemard-Verger Alexandra , Wu Christian , Durand Aurélie , Level Théo , Giraud Léa , Lombès Amélie , Germain Mathieu , Pierre Rémi , Saintpierre Benjamin , Lambert Mireille , Auffray Cédric , Peyssonnaux Carole , Goldwasser François , Vaulont Sophie , Alves-Guerra Marie-Clotilde , Dentin Renaud , Lucas Bruno , Martin Bruno
Published: September 2024

Impact of iron supplementation on CD71 expression by T cells in vivo.
Data from MerTK Induces Dysfunctional Dendritic Cells by Metabolic Reprogramming
Authors: Zewdie Eden Y. , Edwards George M. , Hunter Debra M. , Earp Henry Shelton , Holtzhausen Alisha
Published: September 2024

Abstract
Checkpoint inhibitors, specifically anti–programmed cell death protein 1 (PD1), have shown success in treating metastatic melanoma; however, some patients develop resistance. Dendritic cells (DC) play a key role in initiating an immune response, but in certain circumstances they become ineffective. We investigated the role of MerTK, a receptor tyrosine kinase responsible for myeloid cell clearance of dead cells, in the regulation of DC function and metabolism in the tumor microenvironment. Tumors resistant to anti-PD1 exhibited increased levels of MerTK+ DCs. Treating wild-type DCs with apoptotic melanoma cells in vitro resulted in increased MerTK expression, elevated mitochondrial respiration and fatty acid oxidation, and reduced T-cell stimulatory capacity, all characteristics of dysfunctional DCs. In contrast, dead cells had only limited effect on the metabolism of MerTK-deficient DCs, which instead maintained an antigen-presenting, stimulatory phenotype. The efficacy of anti-PD1 to slow tumor progression and induce antigen specific T-cell infiltration was markedly increased in mice with selective ablation of MerTK in the DC compartment, suggesting the possibility of therapeutically targeting MerTK to modulate DC metabolism and function and enhance anti-PD1 therapy.
Data from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy
Authors: Porte Sarah , Audemard-Verger Alexandra , Wu Christian , Durand Aurélie , Level Théo , Giraud Léa , Lombès Amélie , Germain Mathieu , Pierre Rémi , Saintpierre Benjamin , Lambert Mireille , Auffray Cédric , Peyssonnaux Carole , Goldwasser François , Vaulont Sophie , Alves-Guerra Marie-Clotilde , Dentin Renaud , Lucas Bruno , Martin Bruno
Published: September 2024

Abstract
Cancers only develop if they escape immunosurveillance, and the success of cancer immunotherapies relies in most cases on their ability to restore effector T-cell functions, particularly IFNγ production. Revolutionizing the treatment of many cancers, immunotherapies targeting immune checkpoints such as PD1 can increase survival and cure patients. Unfortunately, although immunotherapy has greatly improved the prognosis of patients, not all respond to anti-PD1 immunotherapy, making it crucial to identify alternative treatments that could be combined with current immunotherapies to improve their effectiveness. Here, we show that iron supplementation significantly boosts T-cell responses in vivo and in vitro. The boost was associated with a metabolic reprogramming of T cells in favor of lipid oxidation. We also found that the “adjuvant” effect of iron led to a marked slowdown of tumor cell growth after tumor cell line transplantation in mice. Specifically, our results suggest that iron supplementation promotes antitumor responses by increasing IFNγ production by T cells. In addition, iron supplementation improved the efficacy of anti-PD1 cancer immunotherapy in mice. Finally, our study suggests that, in patients with cancer, the quality and efficacy of the antitumor response following anti-PD1 immunotherapy may be modulated by plasma ferritin levels. In summary, our results suggest the benefits of iron supplementation on the reactivation of antitumor responses and support the relevance of a fruitful association between immunotherapy and iron supplementation.
Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
Authors: Kim Bu Gyeom , Kim Bo Ram , Kim Dae Yeong , Kim Woo Young , Kang Sanghee , Lee Sun Il , Oh Sang Cheul
Published: September 2024

The treatment of patients with triple-negative breast cancer (TNBC) relies on cytotoxic therapy. Currently, atezolizumab and chemotherapy can be combined in patients with TNBC. However, this approach is not effective for all patients, with many tumors showing low responsiveness to atezolizumab. As there is a lack of alternative treatment options, new anticancer drugs are urgently needed to enhance atezolizumab activity against TNBC. Recent strategies have focused on regulating the expression of programmed cell death ligand 1 (PD-L1) or enhancing immune response activation by combining anticancer drugs with immune checkpoint inhibitors. Cannabidiol (CBD), a cannabinoid component derived from the cannabis plant, has been reported to have anticancer therapeutic potential because of its capacity to induce apoptotic cell death in tumor cells while avoiding cytotoxicity in normal cells. Previous studies have demonstrated the effects of CBD on apoptosis in various cancer cell types. However, the potential role of CBD as an immune modulator in the regulation of PD-L1 expression and anticancer immune responses remains to be explored. In this study, we found that CBD stimulated PD-L1 expression in TNBC cells and that this occurred downstream of CBD-mediated cyclic guanosine monophosphate-adenosine monophosphate synthase–stimulator of interferon genes (cGAS–STING) pathway activation. Taken together, we have demonstrated that the combination of CBD and anti–PD-L1 enhances the anticancer immune responses in in vitro and in vivo experiments. Our findings identified the mechanism of PD-L1 regulation by CBD in TNBC cells and suggested that CBD could be a potential candidate for the development of new combinatorial strategies with immune checkpoint inhibitors in patients with TNBC.
Table S4 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Authors: Meriranta Leo , Sorri Selma , Huse Kanutte , Liu Xiaonan , Spasevska Ivana , Zafar Sadia , Chowdhury Iftekhar , Dufva Olli , Sahlberg Eerika , Tandarić Luka , Karjalainen-Lindsberg Marja-Liisa , Hyytiäinen Marko , Varjosalo Markku , Myklebust June H. , Leppä Sirpa
Published: September 2024

Table S4 shows data from the analysis of protein-protein interactions of KLHL6 identified with proximity-ligation with C-terminal BioID2 constructs.
Data from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Authors: Meriranta Leo , Sorri Selma , Huse Kanutte , Liu Xiaonan , Spasevska Ivana , Zafar Sadia , Chowdhury Iftekhar , Dufva Olli , Sahlberg Eerika , Tandarić Luka , Karjalainen-Lindsberg Marja-Liisa , Hyytiäinen Marko , Varjosalo Markku , Myklebust June H. , Leppä Sirpa
Published: September 2024

Abstract
Pathomechanisms that activate oncogenic B-cell receptor (BCR) signaling in diffuse large B-cell lymphoma (DLBCL) are largely unknown. Kelch-like family member 6 (KLHL6) encoding a substrate-adapter for Cullin-3-RING E3 ubiquitin ligase with poorly established targets is recurrently mutated in DLBCL. By applying high-throughput protein interactome screens and functional characterization, we discovered that KLHL6 regulates BCR by targeting its signaling subunits CD79A and CD79B. Loss of physiologic KLHL6 expression pattern was frequent among the MCD/C5-like activated B-cell DLBCLs and was associated with higher CD79B levels and dismal outcome. Mutations in the bric-a-brac tramtrack broad domain of KLHL6 disrupted its localization and heterodimerization and increased surface BCR levels and signaling, whereas Kelch domain mutants had the opposite effect. Malfunctions of KLHL6 mutants extended beyond proximal BCR signaling with distinct phenotypes from KLHL6 silencing. Collectively, our findings uncover how recurrent mutations in KLHL6 alter BCR signaling and induce actionable phenotypic characteristics in DLBCL.

Significance: Oncogenic BCR signaling sustains DLBCL cells. We discovered that Cullin-3-RING E3 ubiquitin ligase substrate-adapter KLHL6 targets BCR heterodimer (CD79A/CD79B) for ubiquitin-mediated degradation. Recurrent somatic mutations in the KLHL6 gene cause corrupt BCR signaling by disrupting surface BCR homeostasis. Loss of KLHL6 expression and mutant-induced phenotypes associate with targetable disease characteristics in B-cell lymphoma.

See related commentary by Leveille et al.

See related commentary by Corcoran et al.